Markt oder Branche auswählen:
Chart-Typ:
Zeitraum:
| TeneoBio, Inc: Teneobio Announces FDA Clearance of IND for TNB-585 and Initiation of Phase I Clinical Studies for Metastatic Castrate Resistant Prostate Cancer | NEWARK, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoThree, Inc. announced today that their investigational new drug application (IND) for TNB-585, a bispecific... ► Artikel lesen |
| TeneoBio, Inc: Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma | NEWARK, Calif., Dec. 07, 2020) evaluating TNB-383B in Relapsed Refractory Multiple Myeloma (R/R MM) on December 5 at the 62nd American Society of Hematology Annual Conference. TNB-383B is a fully human... ► Artikel lesen |
| TeneoBio, Inc: Teneobio Announces the Presentation of Interim Phase I Data on TNB-383B (Anti-BCMAxCD3) at the 62nd Annual Meeting of the American Society of Hematology | NEWARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Teneobio Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, today announced... ► Artikel lesen |
| Tellimer adds Asia equity experts CGS-CIMB to global Insights network | LONDON, Sept. 10, 2020 /PRNewswire/ -- Tellimer Group ("Tellimer), the London-headquartered financial information & data platform today announces the addition of CGS-CIMB, a global leader... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
